Elevated Angiogenic Cytokines in Cancer Patients
Author Information
Author(s): LY Dirix, PB Vermeulen, A Pawinski, A Prov63, I Benoy, C De Pooter, M Martin, AT Van Oosterom
Primary Institution: Catholic University of Leuven
Hypothesis
The study investigates the association of serum bFGF and VEGF levels with clinical parameters of disease progression in metastatic cancer patients.
Conclusion
The study found that elevated serum levels of bFGF and VEGF are associated with disease progression in cancer patients.
Supporting Evidence
- 57% of untreated patients had elevated serum levels of one or both angiogenic factors.
- 58% of patients with progressive disease had elevated bFGF and/or VEGF levels compared to 15% of responding patients.
- Two-thirds of patients with progressive disease had increasing serum levels of angiogenic factors.
Takeaway
Doctors found that many cancer patients have higher levels of certain proteins in their blood that help tumors grow. This could help them understand how fast the cancer is getting worse.
Methodology
Serum samples were taken from 146 patients and analyzed for bFGF and VEGF levels using ELISA.
Limitations
The study may not account for all factors influencing angiogenic factor levels, and the sample size may limit generalizability.
Participant Demographics
Patients included 90 untreated and 42 treated metastatic cancer patients with various tumor types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website